

BioLife Solutions Names Roderick de Greef Chief Financial Officer & Secretary

BOTHELL, Wash., May 4, 2016 /PRNewswire/ -- [BioLife Solutions](#), Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue [hypothermic storage](#) and [cryopreservation freeze media](#) and a related [cloud hosted biologistics](#) cold chain management app for [smart shippers](#), today announced that Roderick de Greef has transitioned from Interim Chief Financial Officer and Secretary to full time employment and is relocating to the Seattle area.

De Greef previously served on BioLife's board of directors for over a decade through 2013. Over the last 30 years, Mr. de Greef has held a number of senior executive financial positions and served on the boards of several public companies including Endologix, Cambridge Heart, Cardiac Science, Elephant Talk Communications, and BioLife Solutions. Mr. de Greef has been involved in numerous domestic and international M&A and financing transactions. He currently serves as the Chairman of the Audit Committee for publicly traded Elephant Talk Communications.

Mike Rice, BioLife's President & CEO, said, "I am thrilled that Rod has transitioned to full time employment with BioLife. He brings tremendous professional experience and familiarity with our operations. At this exciting and critical inflection point, I'm confident he will make significant contributions in finance and strategy as we grow our core biopreservation media franchise and partner with early adopters of the evo™ Smart Shipper and our biologistex™ SaaS."

Mr. de Greef commented on joining BioLife by stating, "Having been deeply involved in finance, operations, and strategy of BioLife over the last two months, it's clear that we are very well positioned for growth. Our core biopreservation media business is strong and has great potential as the cell therapy market matures over the next few years. Our biologistex cold chain SaaS is a potentially disruptive and a very complementary offering that also supports our customers in their quest to bring novel time and temperature sensitive cell based therapies to market. I'm looking forward to working with Mike, the board, and our finance team to meet our objectives for 2016 and beyond."

Mr. de Greef received a Bachelor of Arts in Economics and International Relations from San Francisco State University and a Masters of Business Administration from the University of Oregon.

About BioLife Solutions:

Our proprietary HypoThermosol® and CryoStor® biopreservation media products are critical enabling reagents used in the biobanking, drug discovery, and regenerative medicine markets. Our products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. These products provide commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. Our related biologistex cloud hosted biologistics cold chain management app for smart shippers offers enhanced track, trace, and notification services for shipments of time and temperature sensitive biologic materials. We also perform contract aseptic media formulation, fill, and finish services. For more information please visit www.biolifesolutions.com, and follow BioLife on [Twitter](#).

This press release contains forward-looking statements, including, but not limited to, statements concerning potential growth, business opportunities and the potential utility of and market for its products and services. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding the performance of customers' clinical trials; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Media & Investor Relations

Roderick de Greef
Chief Financial Officer
(425) 402-1400
rdegreef@biolifesolutions.com

SOURCE BioLife Solutions, Inc.

<https://investors.biolifesolutions.com/2016-05-04-BioLife-Solutions-Names-Roderick-de-Greef-Chief-Financial-Officer-Secretary>